EGFR and non-small cell lung carcinoma: Subsequently, on 23 June 2025, it received accelerated approval for EGFR-mutant non-small-cell lung cancer (NSCLC) based on findings from the TROPION-Lung05 and TROPION-Lung01 studies [5,6].